<table id="t12" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 12: Clinically Important Drug Interactions with SAPHRIS
</caption>
<col align="left" width="25.500%"></col>
<col align="left" width="44.933%"></col>
<col align="left" width="29.567%"></col>
<tbody>
<tr>
<td align="center" stylecode="Toprule Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Concomitant Drug Name or Drug Class</content>
</td>
<td align="center" stylecode="Toprule Botrule Rrule" valign="top">
<content stylecode="bold">Clinical Rationale</content>
</td>
<td align="center" stylecode="Toprule Botrule Rrule" valign="top">
<content stylecode="bold">Clinical Recommendation</content>
</td>
</tr>
<tr>
<td align="justify" stylecode="Botrule Lrule Rrule" valign="top">Antihypertensive Drugs<br/>
</td>
<td align="justify" stylecode="Botrule Rrule" valign="top">Because of its Î±<sub>1</sub>-adrenergic antagonism with potential for inducing hypotension, SAPHRIS may enhance the effects of certain antihypertensive agents <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#s30">5.7</linkhtml>)]</content>.
</td>
<td align="justify" stylecode="Botrule Rrule" valign="top">Monitor blood pressure and adjust dosage of antihypertensive drug accordingly.
</td>
</tr>
<tr>
<td align="justify" stylecode="Botrule Lrule Rrule" valign="top">Strong CYP1A2 Inhibitors (e.g., Fluvoxamine)
</td>
<td align="justify" stylecode="Botrule Rrule" valign="top">SAPHRIS is metabolized by CYP1A2. Marginal increase of asenapine exposure was observed when SAPHRIS is used with fluvoxamine at 25 mg administered twice daily <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#s94">12.3</linkhtml>)]</content>. However, the tested fluvoxamine dose was suboptimal. Full therapeutic dose of fluvoxamine is expected to cause a greater increase in asenapine exposure.
</td>
<td align="justify" stylecode="Botrule Rrule" valign="top">Dosage reduction for SAPHRIS based on clinical response may be necessary.
</td>
</tr>
<tr>
<td align="justify" stylecode="Botrule Lrule Rrule" valign="top">CYP2D6 substrates and inhibitors (e.g., paroxetine)
</td>
<td align="justify" stylecode="Botrule Rrule" valign="top">SAPHRIS may enhance the inhibitory effects of paroxetine on its own metabolism. Concomitant use of paroxetine with SAPHRIS increased the paroxetine exposure by 2-fold as compared to use paroxetine alone <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#s94">12.3</linkhtml>)].</content>
</td>
<td align="justify" stylecode="Botrule Rrule" valign="top">Reduce paroxetine dose by half when paroxetine is used in combination with SAPHRIS.
</td>
</tr>
</tbody>
</table>